EUVIMEDEUVIMED entdecken
Open Access

WASOG Clinical Trial Endpoint Task Force: Executive Summary.

Robert P Baughman, Elyse E Lower, Daniel A Culver, Marc A Judson, Athol U Wells

Sarcoidosis vasculitis and diffuse lung diseases · 30.09.2025 · 42 (3) · 17859-17859

DOI: 10.36141/svdld.v42i3.17859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoidosis vasculitis and diffuse lung diseases, erschienen am 30.09.2025. Verfasst von Robert P Baughman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Editor-in-chief, Sarcoidosis, Vasculitis and Diffuse Lung Diseases; University of Cincinnati, Department of Medicine, Cincinnati, OH, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past few years, an increased number of clinical trials have been performed evaluating specific therapies for pulmonary and cardiac sarcoidosis. However, a lack of consensus remains for appropriate clinical trial endpoints. In 2024, the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) established a clinical trial endpoint Task Force to update the 2011 WASOG Task Force. This initiative was spearheaded by five sarcoidosis specialists (RPB, EEL, DAC, MAJ, AUW) and enlisted a total of 55 stakeholders, including 37 health care providers, 14 industry representatives, and 4 patients. In March 2025, 46 stakeholders participated in a one-day meeting which included twenty focused talks regarding clinical trial endpoints for pulmonary and cardiac sarcoidosis trials. A compilation of individual talk summaries was prepared and distributed to all stakeholders, including those unable to attend the meeting. Based on feedback from all stakeholders, the team leaders developed a series of statements reflecting the presentations and discussions with subsequent anonymous voting by all stakeholders. The majority of the voters endorsed thirteen specific clinical trial endpoint statements: two evaluating overall trial design, seven regarding pulmonary sarcoidosis, and four discussing cardiac sarcoidosis.

Schlagwörter

sarcoidosisclinical trial endpointspulmonary sarcoidosiscardiac sarcoidosisconsensus statementtrial designstakeholder consensusgranulomatous disease

Autor:innen und Institutionen

  • Editor-in-chief, Sarcoidosis, Vasculitis and Diffuse Lung Diseases; University of Cincinnati, Department of Medicine, Cincinnati, OH, USA.
  • University of Cincinnati, Department of Medicine, Cincinnati, OH, USA.
  • Department of Pulmonary Medicine and Critical Care, Cleveland Clinic, Cleveland, OH, USA.
  • Albany Medical College, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Albany, NY, USA.
  • Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; National Heart and Lung Institute, Imperial College London, London, UK; Margaret Turner Warwick Centre for Fibrosing Lung Disease, Imperial College Lo…

Zitieren

APA

Baughman, R. P., Lower, E. E., Culver, D. A., Judson, M. A., & Wells, A. U. (2025). WASOG Clinical Trial Endpoint Task Force: Executive Summary. Sarcoidosis vasculitis and diffuse lung diseases, 42(3), 17859-17859. https://doi.org/10.36141/svdld.v42i3.17859

Vancouver

Baughman RP, Lower EE, Culver DA, Judson MA, Wells AU. WASOG Clinical Trial Endpoint Task Force: Executive Summary. Sarcoidosis vasculitis and diffuse lung diseases. 2025;42(3):17859-17859. doi:10.36141/svdld.v42i3.17859

BibTeX
@article{Baughman2025,
  author = {Baughman, Robert P and Lower, Elyse E and Culver, Daniel A and Judson, Marc A and Wells, Athol U},
  title = {WASOG Clinical Trial Endpoint Task Force: Executive Summary},
  journal = {Sarcoidosis vasculitis and diffuse lung diseases},
  year = {2025},
  volume = {42},
  number = {3},
  pages = {17859--17859},
  doi = {10.36141/svdld.v42i3.17859}
}
Kostenlos starten →